Trevi Therapeutics (TRVI) News Today $6.14 +0.02 (+0.25%) As of 10:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Trevi Therapeutics Stockholders Approve Key AmendmentsJune 17 at 5:42 PM | tipranks.comQ2 EPS Estimate for Trevi Therapeutics Lifted by AnalystJune 15 at 1:45 AM | americanbankingnews.comLeerink Partnrs Has Bullish Forecast for TRVI Q2 EarningsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Stock analysts at Leerink Partnrs raised their Q2 2025 earnings estimates for shares of Trevi Therapeutics in a research note issued on Wednesday, June 11th. Leerink Partnrs analyst F. Khurshid now expects that the company will earn ($0.08) pJune 13, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Trading Down 4.8% - Time to Sell?Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 4.8% - Time to Sell?June 9, 2025 | marketbeat.comTwo Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Two Sigma Investments LP bought a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 135,807 shares of the company's stock, valued at approximately $560,June 9, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell"June 8, 2025 | americanbankingnews.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLCMillennium Management LLC boosted its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 774.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 180,419 shares of the company's stock aftJune 7, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street ZenWall Street Zen cut Trevi Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday.June 7, 2025 | marketbeat.comTrevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesJune 5, 2025 | prnewswire.comAmeriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)Ameriprise Financial Inc. grew its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 187.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 96,784 shares of the company's stock after acquiJune 5, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Time to Buy?Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Here's WhyJune 4, 2025 | marketbeat.comTrevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockJune 3, 2025 | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Stock Price Down 7.1% - Here's WhyTrevi Therapeutics (NASDAQ:TRVI) Trading Down 7.1% - Here's WhyJune 3, 2025 | marketbeat.comTrevi Therapeutics Announces Proposed Public Offering of Common StockJune 2, 2025 | prnewswire.comTrevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease PatientsJune 2, 2025 | benzinga.comTrevi Therapeutics (NASDAQ:TRVI) Reaches New 12-Month High - What's Next?Trevi Therapeutics (NASDAQ:TRVI) Sets New 52-Week High - Here's What HappenedJune 2, 2025 | marketbeat.comTrevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Monday.June 2, 2025 | marketbeat.comTrevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 2, 2025 | prnewswire.comTrevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 1, 2025 | prnewswire.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by AnalystsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned a consensus rating of "Buy" from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and three have given a strong buy recommeJune 1, 2025 | marketbeat.comResearch Analysts Issue Forecasts for TRVI Q2 EarningsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Trevi Therapeutics in a research note issued on Wednesday, May 28th. HC Wainwright analyst B. Folkes forecasts that the company will pMay 31, 2025 | marketbeat.comH.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy RatingMay 29, 2025 | msn.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Still a Buy?Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Should You Buy?May 29, 2025 | marketbeat.comHC Wainwright Begins Coverage on Trevi Therapeutics (NASDAQ:TRVI)HC Wainwright assumed coverage on Trevi Therapeutics in a research note on Wednesday. They issued a "buy" rating and a $21.00 price objective on the stock.May 29, 2025 | marketbeat.comTrevi Therapeutics to Participate in Upcoming June ConferencesMay 29, 2025 | prnewswire.comNorthern Trust Corp Raises Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Northern Trust Corp raised its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 11.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 482,815 shares of the company's stock after buyingMay 27, 2025 | marketbeat.comWoodline Partners LP Buys 2,606,370 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)Woodline Partners LP grew its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 429.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,212,597 shares of the company's stock after acquiring an additioMay 24, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Boosts Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Frazier Life Sciences Management L.P. raised its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 44.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,664,774 shares of the company's stock after buying an additional 3,28May 23, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)Needham & Company LLC reiterated a "buy" rating and set a $24.00 price objective on shares of Trevi Therapeutics in a report on Tuesday.May 22, 2025 | marketbeat.comVR Adviser LLC Reduces Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)VR Adviser LLC lessened its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 63.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,266,457 shares of the company'sMay 22, 2025 | marketbeat.comTrevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic CoughMay 20, 2025 | prnewswire.comPoint72 Asset Management L.P. Takes Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Point72 Asset Management L.P. bought a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,150,237 shares of theMay 20, 2025 | marketbeat.comCubist Systematic Strategies LLC Invests $368,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Cubist Systematic Strategies LLC purchased a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 89,309 shares of the company's stock, valued at apprMay 19, 2025 | marketbeat.comDimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Dimensional Fund Advisors LP boosted its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 86.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 134,353 shares of the company's stock after purchasing an additionalMay 19, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Holdings Increased by MPM Bioimpact LLCMPM Bioimpact LLC lifted its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 101.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,094,896 shares of the company's stock after purcMay 16, 2025 | marketbeat.comTrevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comBarclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Barclays PLC grew its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 64.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 156,267 shares of the company's stock after buying an adMay 10, 2025 | marketbeat.comTrevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finanznachrichten.deTrevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from AnalystsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has earned a consensus rating of "Buy" from the ten analysts that are covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and three have given a strong buy recommendation toMay 9, 2025 | marketbeat.comMarshall Wace LLP Sells 38,203 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)Marshall Wace LLP lowered its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 47.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,921 shares of the company's stock after selling 38,203 shares duriMay 8, 2025 | marketbeat.comAlly Bridge Group NY LLC Lowers Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Ally Bridge Group NY LLC cut its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 40.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 781,489 shares of the company's stock after selling 541,311 shares duMay 4, 2025 | marketbeat.comAcuta Capital Partners LLC Has $3.18 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Acuta Capital Partners LLC increased its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 165.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 771,958 shares ofMay 4, 2025 | marketbeat.comAcorn Capital Advisors LLC Invests $8.24 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Acorn Capital Advisors LLC acquired a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 2,001,048 shares of the company's stock, valued at approximately $8,244,000. Trevi Therapeutics makes uMay 4, 2025 | marketbeat.comBoothbay Fund Management LLC Takes $387,000 Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Boothbay Fund Management LLC acquired a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 93,859 shares of the company's stock, valuMay 4, 2025 | marketbeat.comTrevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025May 1, 2025 | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Here's WhyTrevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading Volume - Time to Buy?May 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Takes Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Adage Capital Partners GP L.L.C. purchased a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 2,500,000 shares of the company's stock, valued at approApril 30, 2025 | marketbeat.comJPMorgan Chase & Co. Boosts Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)JPMorgan Chase & Co. increased its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 120.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 221,664 shares of the company's stock after acquiringApril 30, 2025 | marketbeat.comXTX Topco Ltd Makes New Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)XTX Topco Ltd acquired a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 67,201 shares of the company's stock, valued at approximately $277,000. XTX TopApril 28, 2025 | marketbeat.com Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address TRVI Media Mentions By Week TRVI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRVI News Sentiment▼0.720.56▲Average Medical News Sentiment TRVI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRVI Articles This Week▼65▲TRVI Articles Average Week Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HCM News CRNX News CPRX News MOR News MTSR News ALVO News AAPG News IBRX News MLTX News OGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRVI) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Shocking Link Between A.I. and Your MoneyThe AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRVI Stock Free TRVI Stock Alerts